Vir Biotechnology, Inc. Payments to Acquire Investments
Vir Biotechnology, Inc. (VIR) reported Payments to Acquire Investments of $510.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-05
- Vir Biotechnology, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $352.10M, a 83.03% increase year-over-year.
- Vir Biotechnology, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $158.37M, a 8.82% decline year-over-year.
- Vir Biotechnology, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $255.82M, a 59.03% increase year-over-year.
- Vir Biotechnology, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $264.45M, a 10.12% increase year-over-year.
- Vir Biotechnology, Inc. payments to acquire investments for fiscal 2025 was $886.33M, a 28.25% decline from fiscal 2024.
- Vir Biotechnology, Inc. payments to acquire investments for fiscal 2024 was $1.24B, a 38.73% decline from fiscal 2023.
- Vir Biotechnology, Inc. payments to acquire investments for fiscal 2023 was $2.02B, a 36.51% increase from fiscal 2022.
- Vir Biotechnology, Inc. payments to acquire investments for fiscal 2022 was $1.48B, a 251.46% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $352.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $510.47M 10-Q · filed 2026-08-05 | $766.29M derived: sum of 3 quarters · filed 2026-08-05 | $1.03B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $158.37M 10-Q · filed 2026-05-07 | $414.20M derived: sum of 2 quarters · filed 2026-05-07 | $678.64M derived: sum of 3 quarters · filed 2026-05-07 | $871.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $255.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $520.27M derived: sum of 2 quarters · filed 2026-02-23 | $712.64M derived: sum of 3 quarters · filed 2026-08-05 | $886.33M 10-K · filed 2026-02-23 |
| 2025-09-30 | $264.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $456.82M derived: sum of 2 quarters · filed 2026-08-05 | $630.51M 10-Q · filed 2025-11-05 | $791.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $192.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $366.06M 10-Q · filed 2026-08-05 | $526.92M derived: sum of 3 quarters · filed 2026-08-05 | $767.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $173.69M 10-Q · filed 2026-05-07 | $334.55M derived: sum of 2 quarters · filed 2026-05-07 | $574.69M derived: sum of 3 quarters · filed 2026-05-07 | $846.09M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $160.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $401.00M derived: sum of 2 quarters · filed 2026-02-23 | $672.40M derived: sum of 3 quarters · filed 2026-02-23 | $1.24B 10-K · filed 2026-02-23 |
| 2024-09-30 | $240.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $511.54M derived: sum of 2 quarters · filed 2025-11-05 | $1.07B 10-Q · filed 2025-11-05 | $1.89B derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $271.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $834.34M 10-Q · filed 2025-08-06 | $1.65B derived: sum of 3 quarters · filed 2026-02-23 | $2.16B derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $562.94M 10-Q · filed 2025-05-08 | $1.38B derived: sum of 2 quarters · filed 2026-02-23 | $1.88B derived: sum of 3 quarters · filed 2026-02-23 | $2.19B derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $818.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.32B derived: sum of 2 quarters · filed 2026-02-23 | $1.63B derived: sum of 3 quarters · filed 2026-02-23 | $2.02B 10-K · filed 2026-02-23 |
| 2023-09-30 | $502.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $812.69M derived: sum of 2 quarters · filed 2024-11-04 | $1.20B 10-Q · filed 2024-11-04 | $1.60B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $309.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $694.29M 10-Q · filed 2024-08-01 | $1.10B derived: sum of 3 quarters · filed 2025-02-27 | $1.83B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $384.51M 10-Q · filed 2024-05-03 | $791.73M derived: sum of 2 quarters · filed 2025-02-27 | $1.52B derived: sum of 3 quarters · filed 2025-02-27 | $1.77B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $407.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.14B derived: sum of 2 quarters · filed 2025-02-27 | $1.39B derived: sum of 3 quarters · filed 2025-02-27 | $1.48B 10-K · filed 2025-02-27 |
| 2022-09-30 | $728.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $980.19M derived: sum of 2 quarters · filed 2023-11-03 | $1.07B 10-Q · filed 2023-11-03 | $1.43B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $251.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $341.29M 10-Q · filed 2023-08-04 | $705.80M derived: sum of 3 quarters · filed 2024-02-26 | $705.80M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $89.56M 10-Q · filed 2023-05-08 | $454.07M derived: sum of 2 quarters · filed 2024-02-26 | $454.07M derived: sum of 3 quarters · filed 2024-02-26 | $504.80M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $364.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $364.51M derived: sum of 2 quarters · filed 2024-02-26 | $415.24M derived: sum of 3 quarters · filed 2024-02-26 | $420.24M 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $50.73M derived: sum of 2 quarters · filed 2022-11-03 | $55.73M 10-Q · filed 2022-11-03 | $96.17M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $50.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $55.73M 10-Q · filed 2022-08-09 | $96.17M derived: sum of 3 quarters · filed 2023-02-28 | $329.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $5.00M 10-Q · filed 2022-05-05 | $45.44M derived: sum of 2 quarters · filed 2023-02-28 | $278.94M derived: sum of 3 quarters · filed 2023-02-28 | $368.37M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $40.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $273.94M derived: sum of 2 quarters · filed 2023-02-28 | $363.37M derived: sum of 3 quarters · filed 2023-02-28 | $403.84M 10-K · filed 2023-02-28 |
| 2020-09-30 | $233.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $322.93M derived: sum of 2 quarters · filed 2021-11-04 | $363.40M 10-Q · filed 2021-11-04 | $511.36M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $89.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $129.90M 10-Q · filed 2021-08-05 | $277.86M derived: sum of 3 quarters · filed 2022-02-28 | $413.78M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $40.47M 10-Q · filed 2021-05-06 | $188.44M derived: sum of 2 quarters · filed 2022-02-28 | $324.35M derived: sum of 3 quarters · filed 2022-02-28 | $361.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $147.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $283.88M derived: sum of 2 quarters · filed 2022-02-28 | $321.07M derived: sum of 3 quarters · filed 2022-02-28 | $643.90M 10-K · filed 2022-02-28 |
| 2019-09-30 | $135.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $173.10M derived: sum of 2 quarters · filed 2020-11-10 | $495.93M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $37.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $360.02M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $322.83M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $123.11M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |